TBF1 Stock Overview
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Canntab Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.024 |
| 52 Week Low | CA$0.0005 |
| Beta | 1.17 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.92% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| TBF1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -6.0% | -1.3% |
| 1Y | 0% | -31.5% | 4.1% |
Rentabilidad frente al sector: TBF1 superó al sector German Pharmaceuticals , que obtuvo un rendimiento del -25.2% el año pasado.
Rentabilidad vs. Mercado: TBF1 obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.
Price Volatility
| TBF1 volatility | |
|---|---|
| TBF1 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: TBF1ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de TBF1 en el último año.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Richard Goldstein | https://canntab.ca |
Canntab Therapeutics Limited Fundamentals Summary
| TBF1 fundamental statistics | |
|---|---|
| Market cap | €132.99k |
| Earnings (TTM) | -€2.29m |
| Revenue (TTM) | €50.23k |
2.6x
P/S Ratio-0.1x
P/E RatioIs TBF1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBF1 income statement (TTM) | |
|---|---|
| Revenue | CA$73.48k |
| Cost of Revenue | CA$1.40m |
| Gross Profit | -CA$1.33m |
| Other Expenses | CA$2.03m |
| Earnings | -CA$3.36m |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | -1,806.30% |
| Net Profit Margin | -4,566.80% |
| Debt/Equity Ratio | -87.8% |
How did TBF1 perform over the long term?
See historical performance and comparison